

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/011007

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>					
IPC 7	G01N33/50	G01N33/68	A61K48/00	A61K38/00	A61K39/395
C12Q1/68					

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 G01N A61K C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, Sequence Search

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 99/36550 A (INCYTE PHARMACEUTICALS, INC; BANDMAN, OLGA; HILLMAN, JENNIFER, L; YUE,) 22 July 1999 (1999-07-22)</p> <p>Seq Id Nos 12 and 24, p. 25, lines 8 – 26, p. 37, line 11 – p. 38, line 20, p. 40, line 11 – p. 44, line 22, p. 48, line 5 – p. 49, line 6, p. 54, line 27 – p. 55, line 13, claims 1 – 21</p> <p>-----</p>	1–26
A	<p>NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XI. THE COMPLETE SEQUENCES OF 100 NEW cDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO"</p> <p>DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 5, 1998, pages 277–286, XP000828191</p> <p>ISSN: 1340-2838</p> <p>abstract</p> <p>-----</p>	1–26

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the International search	Date of mailing of the International search report
---	--

1 March 2005

12.07.2005

Name and mailing address of the ISA	Authorized officer
-------------------------------------	--------------------

European Patent Office, P.B. 5818 Patentlaan 2  
NL – 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Hoesel, H

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/011007

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claim 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple Inventions in this International application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-18, 24-26 (all in part); 19-23

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-18, 24-26 (all in part.); 19-23

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with cancer  
---

2. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with gastroenterological diseases, i.e. liver cirrhosis  
---

3. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with hematological diseases i.e. spleen liver cirrhosis  
---

4. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with neurological diseases, i.e. Alzheimer's disease  
---

5. claims: 1-18, 24-26 (part.)

use of aminopeptidase-like 1 ("NPEPL1") gene or protein as screening marker / diagnostic marker / therapeutical target in conjunction with urological diseases, i.e. BPH  
---

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2004/011007

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9936550	A 22-07-1999	US 6203979 B1		20-03-2001
		AU 2113599 A		02-08-1999
		CA 2317094 A1		22-07-1999
		EP 1045913 A2		25-10-2000
		JP 2002508970 T		26-03-2002
		WO 9936550 A2		22-07-1999
		US 2003166246 A1		04-09-2003
		US 6432690 B1		13-08-2002
		US 2002086334 A1		04-07-2002